#Shanghai #USA #biopharmaceuticals #ADC #Allink Biotherapeutics

Allink Biotherapeutics' New Milestone in Series A Extension Funding

Allink Biotherapeutics, Inc. has recently achieved a significant milestone by successfully completing its Series A extension funding, raising an impressive $47 million. This funding round was spearheaded by Legend Capital, with substantial participation from Meituan Long-Z Investment. Existing and new investors, including Lanchi Ventures and Yuanbio Venture Capital, have shown tremendous support, signaling their confidence in the company’s innovative approaches in the biopharmaceutical sector.

Aiming for Advanced Clinical Development

The primary goal of this capital infusion is to accelerate Allink Biotherapeutics' global clinical programs, particularly focusing on two of their lead antibody-drug conjugate (ADC) candidates—ALK201 and ALK202. These candidates are noteworthy for their competitive edge in the rapidly evolving market of targeted cancer therapies.

First up is ALK201, a pioneering ADC targeting FGFR2b, which has yielded promising results across multiple tumor types. Its efficacy, paired with a favorable safety profile, positions it as a potential cornerstone therapy for tumors characterized by FGFR2b overexpression. In parallel, preliminary clinical data for ALK202, a bispecific ADC designed to engage both EGFR and cMET, has highlighted its potential relevance in treating non-small cell lung cancer (NSCLC). This bispecific approach also opens the door for exploring a wider array of tumors and patient populations, specifically those identified by specific biomarkers.

Comprehensive Strategy for Clinical Testing

Allink's strategy revolves around a biomarker-driven approach aimed at demonstrating the effectiveness of its lead candidates across a broad spectrum of solid tumors. In the near term, the company plans to initiate combination therapy studies to further investigate the therapeutic potential of ALK201 and ALK202 in a wider population of frontline patients. This will not only prepare these candidates for critical clinical trials but will also position them distinctively within their targeted therapeutic indications.

Innovative Platform Enhancements

Beyond the ADC technology, Allink Biotherapeutics is innovating with its proprietary masked T cell engager (TCE) platform. This technology is designed to modify TCE applications specifically within solid tumors, while the company is also working on a potent pipeline of first-in-class bi- and multispecific antibodies in the immunology sphere. These advancements stem from rational design principles, aiming to meet the needs of patient populations that currently lack effective treatment options.

Investor Confidence and Future Perspectives

Dr. Hui Feng, the founder and CEO of Allink Biotherapeutics, graciously acknowledged the unwavering support of investors during this pivotal stage. He stated, "With this backing, we continue to advance our clinical roadmap and are committed to delivering innovative drug candidates that promise greater value in the near future."

Tan Hong, Managing Director at Legend Capital, expressed confidence in Allink’s efficient execution and development strategy, asserting that the rapid clinical advancement of its leading assets validates the company’s ADC platform, adding significant value for patients and stakeholders alike. Furthermore, Xuejing Guo, Managing Director at Meituan Long-Z Investment, praised Allink’s team for their international outlook and impressive pace in the ADC sector, underlining the potential of their technology to revolutionize treatments and lives worldwide.

Looking Ahead

Founded in 2023, Allink Biotherapeutics is dedicated to the discovery and development of differentiated ADCs and multispecific antibodies targeting oncology and immunology. With its innovative platform and exceptional research capabilities, the company aims to quickly push two ADC candidates into global Phase I clinical trials. Allink remains committed to driving innovation in ADCs to transform the lives of patients who are most in need.

For those interested in following Allink’s progress, updates will be available through their investor relations channels as well as major news outlets covering advancements in biopharmaceuticals.